Clinical Therapy Using iPSCs:Hopes and Challenges  

作　　者：Xiao Lu Tongbiao Zhao 

机构地区：[1]State Key Laboratory of Reproductive Biology,Institute of Zoology,Chinese Academy of Sciences

出　　处：《Genomics, Proteomics & Bioinformatics》2013年第5期294-298,共5页基因组蛋白质组与生物信息学报（英文版）

基　　金：supported by grants from the National Basic Research Program of China(Grant No.2012CB966901);the Strategic Priority Research Program of the Chinese Academy of Sciences(Grant No.XDA01040108);the National Natural Science Foundation of China(Grant No.31271592) to TZ

摘　　要：Induced pluripotent stem cells （iPSCs） are generated by ectopic expression of defined transcription factors in somatic cells. They can undergo unlimited self-renewal and maintain the embryonic stem cells （ESCs）-like ability to differentiate into all three germ layers, iPSCs can poten- tially provide unlimited autologous cells for therapy and therefore hold great promise for regener- ative medicine. Here we reviewed the recent advances in iPSC studies on disease modeling and clinical treatment as well as challenges correlated with clinical development of iPSCs, like tumori- genicity, immunogcnicity and genomic instability.Induced pluripotent stem cells （iPSCs） are generated by ectopic expression of defined transcription factors in somatic cells. They can undergo unlimited self-renewal and maintain the embryonic stem cells （ESCs）-like ability to differentiate into all three germ layers, iPSCs can poten- tially provide unlimited autologous cells for therapy and therefore hold great promise for regener- ative medicine. Here we reviewed the recent advances in iPSC studies on disease modeling and clinical treatment as well as challenges correlated with clinical development of iPSCs, like tumori- genicity, immunogcnicity and genomic instability.

关 键 词：IPSC Regenerative medicineDisease modeling IMMUNOGENICITY Tumorigenicity 

分 类 号：R457[医药卫生—治疗学]